At 10:30, the strategic session "PHARMA 2030: Balancing Innovation, Regulation, and Resources. How to Ensure Russia's Drug Independence" took place in the open hall. The session was moderated by Alexey Kedrin, Chairman of the Association of Pharmaceutical Manufacturers of the EAEU. Alexey opened with a welcome speech, touching upon the "Pharma 2030" strategy.
Maria Komarova, Director of Legal Affairs at Aktivny Component JSC, spoke on the topic "The Russian Pharmaceutical Market: Where Are We and Where Are We Going?" In her presentation, Maria discussed the vision for the development of the pharmaceutical industry strategy and also addressed the debates on how the domestic pharmaceutical industry should be developed. The domestic pharmaceutical sector is currently in a stage of regression. The speaker cited data on packaging sales: over 900 million units in 2020, and only 500 million in 2025. Maria also touched upon the current situation in the Middle East, emphasizing how it has affected drug supplies, concluding that it is time to develop local production.
Dmitry Nakhamehen, Director of Government Relations and Market Access at GEROPHARM LLC, presented a report on "Real Steps Towards Drug Security." Dmitry raised the issue of drug security, specifically financial affordability and the physical capability of producing pharmaceutical drugs within our country.
Alexey Kartashov, Director of Government Relations at IIHR LLC (ChemRar Group), presented on the topic: "Pharmaceuticals at a Crossroads: Innovation, Patents, and Generics — Where to Find Balance for the Nation's Health?" Alexey noted that the pharmaceutical industry currently stands at a crossroads, highlighting the following aspects:
Artyom Gusev, Development Director at Sistema-BioTech LLC, delivered a report on "Import Substitution. Creation of Vital Domestic Drugs Using the SBT-CHO Biotechnological Platform." Artyom noted that the topics previously raised by his colleagues are highly relevant and raised the issue of developers facing a lack of an established culture for implementing new developments, asking how to create a culture and environment where scientific developments can reach the final stage. Issues in the pharmaceutical industry and the implementation of modern technologies are important and integral, and the incorporation of biotechnological components is very significant for our country. The presentation featured the patented SBT-CHO cell line.
Vladimir Luzhanin, Doctor of Pharmaceutical Sciences, Professor, and Rector of the Perm State Pharmaceutical Academy of the Ministry of Health of Russia, spoke on "Pharmaceutical Education in the Context of Ministry of Education and Science Reforms." Vladimir raised the issue of personnel training within the "Pharma 2030" strategy, noting that as a result of implementing the "Pharma 2020" strategy, the number of pharmaceutical enterprises has increased, and they are in acute need of qualified personnel.
The shortage of personnel remains today, but it is gradually being addressed. The speaker shared his conclusion that by the end of 2026, only a few universities will effectively remain that train personnel for the pharmaceutical industry. It is clear that more attention should be paid to pharmaceutical qualifications and to training personnel who will be in demand.
Olga Kravtsova, Deputy Director of the Department for the Development of the Pharmaceutical and Medical Industry at the Ministry of Industry and Trade of Russia, raised the topic of "Innovations in the Pharmaceutical Industry: Plans, Implemented Cases, and Areas of Application." Olga noted that based on current goals and objectives, the implementation of the "Pharma 2030" strategy is on track: a list of strategically significant drugs and the "second extra" rule have been introduced, and work is underway to supplement measures that will further the strategy's implementation.
At the end of the session, Alexey Kedrin answered numerous questions from the audience, summarized the results of the session, and thanked the organizers and all those present.
Maria Komarova, Director of Legal Affairs at Aktivny Component JSC, spoke on the topic "The Russian Pharmaceutical Market: Where Are We and Where Are We Going?" In her presentation, Maria discussed the vision for the development of the pharmaceutical industry strategy and also addressed the debates on how the domestic pharmaceutical industry should be developed. The domestic pharmaceutical sector is currently in a stage of regression. The speaker cited data on packaging sales: over 900 million units in 2020, and only 500 million in 2025. Maria also touched upon the current situation in the Middle East, emphasizing how it has affected drug supplies, concluding that it is time to develop local production.
Dmitry Nakhamehen, Director of Government Relations and Market Access at GEROPHARM LLC, presented a report on "Real Steps Towards Drug Security." Dmitry raised the issue of drug security, specifically financial affordability and the physical capability of producing pharmaceutical drugs within our country.
Alexey Kartashov, Director of Government Relations at IIHR LLC (ChemRar Group), presented on the topic: "Pharmaceuticals at a Crossroads: Innovation, Patents, and Generics — Where to Find Balance for the Nation's Health?" Alexey noted that the pharmaceutical industry currently stands at a crossroads, highlighting the following aspects:
- Foreign companies: they are scaling back local clinical trials in the Russian Federation. Since 2022, the number of clinical trials has decreased tenfold.
- Patent disputes: the speaker believes that a patent system is necessary, but everything must be logical.
- Structure of public procurement: data on government procurement was presented and analyzed.
- At the end of his speech, Alexey noted the need to increase the share of domestic drug production in line with the "Pharma 2030" strategy and that focus should be placed on proprietary developments.
Artyom Gusev, Development Director at Sistema-BioTech LLC, delivered a report on "Import Substitution. Creation of Vital Domestic Drugs Using the SBT-CHO Biotechnological Platform." Artyom noted that the topics previously raised by his colleagues are highly relevant and raised the issue of developers facing a lack of an established culture for implementing new developments, asking how to create a culture and environment where scientific developments can reach the final stage. Issues in the pharmaceutical industry and the implementation of modern technologies are important and integral, and the incorporation of biotechnological components is very significant for our country. The presentation featured the patented SBT-CHO cell line.
Vladimir Luzhanin, Doctor of Pharmaceutical Sciences, Professor, and Rector of the Perm State Pharmaceutical Academy of the Ministry of Health of Russia, spoke on "Pharmaceutical Education in the Context of Ministry of Education and Science Reforms." Vladimir raised the issue of personnel training within the "Pharma 2030" strategy, noting that as a result of implementing the "Pharma 2020" strategy, the number of pharmaceutical enterprises has increased, and they are in acute need of qualified personnel.
The shortage of personnel remains today, but it is gradually being addressed. The speaker shared his conclusion that by the end of 2026, only a few universities will effectively remain that train personnel for the pharmaceutical industry. It is clear that more attention should be paid to pharmaceutical qualifications and to training personnel who will be in demand.
Olga Kravtsova, Deputy Director of the Department for the Development of the Pharmaceutical and Medical Industry at the Ministry of Industry and Trade of Russia, raised the topic of "Innovations in the Pharmaceutical Industry: Plans, Implemented Cases, and Areas of Application." Olga noted that based on current goals and objectives, the implementation of the "Pharma 2030" strategy is on track: a list of strategically significant drugs and the "second extra" rule have been introduced, and work is underway to supplement measures that will further the strategy's implementation.
At the end of the session, Alexey Kedrin answered numerous questions from the audience, summarized the results of the session, and thanked the organizers and all those present.